Nano-silver nitrate
PreclinicalSmall molecule
Nano-silver nitrate is one of 26 small molecule programs targeting Emphysema. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Emphysema
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Pulmicort
SSalix
Approved
Serevent
GGlaxo Dba Glaxosmithkline
Approved
Foradil
ViatrisApproved
Advil
KKenvue Brands
Approved
Alpha1-Proteinase Inhibitor
CSL BehringApproved
Pulmicort Pmdi HFA
AstraZenecaApproved
Budesonide/formoterol
AstraZenecaPhase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Benlysta
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nano-silver nitrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMansoura University Hospital